Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Acadia Pharmaceuticals (ACAD) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Acadia Pharmaceuticals | 4.35 Bn | 3.50 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.67% |
| Dec 31, 2025 | 281.13% |
| Sep 30, 2025 | 169.18% |
| Jun 30, 2025 | 40.44% |
| Mar 31, 2025 | -86.79% |
| Dec 31, 2024 | 338.71% |
| Sep 30, 2024 | -1.87% |
| Jun 30, 2024 | 101.69% |
| Mar 31, 2024 | -63.85% |
| Dec 31, 2023 | 170.27% |
| Sep 30, 2023 | -5,950.63% |
| Jun 30, 2023 | 102.59% |
| Mar 31, 2023 | -3.31% |
| Dec 31, 2022 | -53.28% |
| Sep 30, 2022 | 20.12% |
| Jun 30, 2022 | 69.92% |
| Mar 31, 2022 | -142.49% |
| Dec 31, 2021 | -222.49% |
| Sep 30, 2021 | 67.05% |
| Jun 30, 2021 | 33.98% |